DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.17
+8.83%Nov 3, 2026, 23:51 UTC
Denali Therapeutics reported a quarterly loss of $0.64 per share, compared with a loss of $0.74 per share a year earlier.
Source:Oct 30, 2026, 13:30 UTC
The Galien Foundation recognized Denali Therapeutics Inc.’ AVLAYAH (tividenofusp alfa-eknm) as the 2026 Best Biotechnology Product.
Source:Oct 22, 2026, 20:01 UTC
Denali Therapeutics announced that it will report its financial results and business highlights for the third quarter ended September 30, 2026, on November 3, 2026.
Source:Aug 13, 2026, 16:13 UTC
Denali Therapeutics launched AVLAYAH, an FDA-approved rare-disease therapy, and reported Q2 2026 revenue of $3.6 million, with projected Q3 revenue tripling due to accelerating patient uptake and payer coverage progress.
Source:Aug 6, 2026, 00:00 UTC
Denali Therapeutics reported Q2 2026 financial results, including AVLAYAH net product revenue of $3.6 million and a net loss of $127.6 million.
Aug 6, 2026, 00:00 UTC
Denali Therapeutics sold a Priority Review Voucher for gross proceeds of $195 million in July 2026.
Jul 28, 2026, 00:00 UTC
Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher to an unnamed large pharmaceutical company on July 27, 2026.
Jun 18, 2026, 00:00 UTC
Denali Therapeutics Inc. agreed to sell its Rare Pediatric Disease Priority Review Voucher to an unnamed buyer for $195 million in cash.
Source: